Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Videos|September 30, 2020
Mental Health and Medical Care Avoidance
Author(s)Judith Feld, MD, MPH, MMM, DLFAPA
Individuals who are anxious and depressed are more likely to avoid necessary medical care, even during a pandemic.
Advertisement
COVID-19 is putting unprecedented pressure on the United States’ healthcare system. But believe it or not, the pandemic is also leading some individuals to delay or even avoid necessary treatment.
Why? The answer may be mental health problems. In her Mental Health Minute, Judith Feld, MD, MPH, MMM, DLFAPA (and National Medical Director at Ontrak) discusses a recent paper, “
Advertisement
Related to this article
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
5